Additional Relevant Details
In June of 2015, the UK Court of Appeal held that Lilly's patent would be indirectly infringed by Actavis marketing certain alternative salt forms of pemetrexed with instructions to dilute the product with saline solution. However, the Court of Appealleft open the question of whether an alternative salt form with instructions to dilute only in dextrose solution would infringe.The court based its decision of non-infringement on Actavis complying with its stated intentions as to how it will market its product and certain circumstances not changing over the remaining life of the patent. In its decision, the UK court accepts that it is not able to predict what will happen in the future and expressly allows either party to ask for the decision to be revisited if there is a material change of circumstances at any point in the remaining life of the patent, which expires in June 2021. Lilly plans to seek permission to appeal today's decision to the UK Court of Appeal.In major European countries, the compound patents for Alimta expired in December 2015. The Alimta vitamin regimen patents expire in June 2021.